Summary
EudraCT Number: 2005-002323-14
Sponsor's Protocol Code Number: 32/2005
National Competent Authority: Iceland - IMCA 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2005-08-24
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002323-14/IS/

A. Protocol Information
A.1 Member State Concerned: Iceland - IMCA
A.2 EudraCT number: 2005-002323-14
A.3 Full title of the trial: Samanburður á þremur meðferðum við áreynsluþvagleka.
A.3.2 Name or abbreviated title of the trial where available: Meðferðir við áreynsluþvagleka
A.4.1 Sponsor's protocol code number: 32/2005
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Landspítali Háskólasjúkrahús
B.1.3.4	Country: Iceland
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.1.1.1 Trade name: Yentreve
D.2.1.1.2 Name of the Marketing Authorisation holder: Eli Lilly á Íslandi
D.2.1.2 Country which granted the Marketing Authorisation: Iceland
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Yentreve
D.3.4 Pharmaceutical form: Capsule, hard
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: duloxitine
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 40 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: Information not present in EudraCT

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Áreynsluþvagleki er þvagleki sem orsakast af líkamlegri áreynslu, hósta eða hnerra.
MedDRA Classification
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Markmið rannsóknarinnar er að bera saman árangur þrenns konar meðferðar við áreynsluþvagleka þ.e. a)grindarbotnsþjálfunar með raförvun, b) grindarbotnsæfinga c) lyfjameðferðar  (yentreve) og grindarbotnsþjálfunar.
 Stefnt er að því að fá 60 konur og verður þeim skipt í 3 jafnstóra hópa með tilviljunaraðferð. Hópur 1 fær grindarbotnsþjálfun með raförvun.  Hópur 2 fær grindarabotnsæfingar eingöngu.  Hópur 3 fær bæði lyf (Yentreve)og grindarbotnsæfingar.  
Með rannsókn þessari er vonast til að fá vísbendingar um gagnsemi ofangreindra meðferðarforma hvors fyrir sig og bera saman hver af þessum þremur meðferðarformum gefi bestan árangur við áreynsluþvagleka.  


E.2.2 Secondary objectives of the trial: 
E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: Þátttakendur verða konur 65 ára og yngri með áreynsluþvagleka sem leitað til lækna og sjúkraþjálfara á LSH. 
E.4 Principal exclusion criteria: Konur sem eru barnshafandi, með barn á brjósti sem hafa farið í skurðaðgerð vegna þvagleka eða eru með krabbamein í blöðru verða útilokaðar frá þátttöku. Einnig þær sem hafa taugaskaða í grindarbotni.  Einnig þær sem falla undir frábendingar lyfsins Yentreve í Sérlyfjaskrá.

Frábendingar skv. Sérlyfjaskrá:
Ofnæmi fyrir virka efninu eða einhverju hjálparefnanna.
Skert lifrarstarfsemi.
Meðganga og brjóstagjöf.

YENTREVE á ekki að nota samhliða ósérhæfðum, óafturkræfum mónóamín oxidasa hemlum - MAO hemlar. 
Ekki ætti að nota YENTREVE samhliða CYP1A2 hemlum, eins og fluvoxamini, ciprofloxacini eða enoxacini, því það veldur hækkaðri plasmaþéttni duloxetins.

E.5 End points
E.5.1 Primary end point(s): Árangur meðferðarinnar verður metinn með vöðvarafriti (EMG), með lífsgæðakvarða og sjálfsmati skjúklings á VAS- skala.
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: Yes
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: No
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): Yes
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: Yes
E.8.2.3.1 Comparator description: Grindarbotnsæfingar og raförvun.
E.8.3 The trial involves single site in the Member State concerned: Yes
E.8.4 The trial involves multiple sites in the Member State concerned: No
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: Líkur eru á að þátttakendur verði innkallaðir til árangursmælinga seinna.
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 2
E.8.9.1 In the Member State concerned months: 
E.8.9.1 In the Member State concerned days: 

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): No
F.1.1.6 Adolescents (12-17 years): No
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: No
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2005-08-24) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 60
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 0
F.4.2.2 In the whole clinical trial: 60
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): Þátttakendum verður boðin sú meðferð sem hefur besta útkomu úr rannsókninni.

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2005-09-01
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2005-07-07

P. End of Trial
P. End of Trial Status: Completed

